Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Francesco_Bellini
|
| gptkbp:acquired |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:dissolved |
gptkb:2010
|
| gptkbp:focus |
central nervous system disorders
cardiovascular diseases infectious diseases pain management gastrointestinal disorders |
| gptkbp:founded |
gptkb:1983
|
| gptkbp:founder |
gptkb:Bill_Wells
|
| gptkbp:headquarters |
gptkb:Mississauga,_Ontario,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biovail Corporation
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:key_people |
gptkb:Bill_Wells
|
| gptkbp:location |
gptkb:Native_American_tribe
|
| gptkbp:products |
extended-release formulations
|
| gptkbp:revenue |
$1.1 billion (2008)
|
| gptkbp:services |
pharmaceutical development
|
| gptkbp:successor |
gptkb:Valeant_Pharmaceuticals_International,_Inc.
|
| gptkbp:symbol |
BVF
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.biovail.com
|